Population Health Learning Network

News Connection 12/19/2016 Opdivo (nivolumab; Bristol-Myers Squibb) was found to increase survival of patients with metastatic or recurrent squamous cell carcinoma of the head and neck. Opdivo (nivolumab; Bristol-Myers Squibb) was found to increase survival of patients with metastatic or recurrent squamous cell carcinoma of the head and neck. Opdivo (nivolumab; Bristol-Myers... 12/19/2016 First Report Managed Care

This article explains how David Silver, MD, chief of urology and director of the Prostate Center at Maimonides Medical Center, changed his treatment decisions amid the pandemic, and highlights the use of the new CPT code for high intensity focused ultrasound that now allows hospitals to bill Medicare and private insurers for reimbursement of the procedure.

Skip to main content Videos Maria C Ospina, MD, movement disorder neurologist, discusses how physicians can ensure they receive all of the information needed to unlock patterns of Parkinson disease among their patients, and breaks down treatment options for OFF episodes for this patient population. Article Info Email Address Name First Last sendto This opens in a new window.

uuid2 Appnexus Registers a unique ID that identifies a returning user's device. The ID is used for targeted ads. 3 months HTTP track/cmf/generic The Trade Desk Presents the user with relevant content and advertisement. The service is provided by third-party advertisement hubs, which facilitate real-time bidding for advertisers.

uuid2 Appnexus Registers a unique ID that identifies a returning user's device. The ID is used for targeted ads. 3 months HTTP track/cmf/generic The Trade Desk Presents the user with relevant content and advertisement. The service is provided by third-party advertisement hubs, which facilitate real-time bidding for advertisers.

News Roctavian, an adeno-associated virus vector-based gene therapy, was approved by the US Food and Drug Administration (FDA) for the treatment of adults with severe hemophilia A without pre-existing antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test. This approval comes after a safety and effectiveness trial showed that Roctavian improved participants’ annualized bleeding rate after 3 years.

By Andrew M. Seaman (Reuters Health) - Nearly three-quarters of U.S. dermatologists received payments worth a collective $34 million from drug companies in 2014, according to a new analysis of a public database. In most cases, the payments were worth less than $50, researchers found. But a few doctors were taking industry payments worth at least $93,622.

By Lorraine L Janeczko NEW YORK (Reuters Health) - Morbidity and mortality after surgery for lower urinary tract symptoms (LUTS) vary depending on the type of surgery, a new study from Germany shows. Open prostatectomy (OP) was associated with the greatest risk of complications, even though it also had a low reintervention rate.

By David Douglas NEW YORK (Reuters Health) - Since guidelines recommended a halt to population-based prostate specific antigen (PSA) screening, there has been a significant drop in the volume of prostate biopsy and radical prostatectomy, according to researchers. The U.S. Preventive Services Task Force (USPSTF) recommended against routine PSA screening in 2012. Dr. Jim C.

By Marilynn Larkin NEW YORK (Reuters Health) - There may be a dose-response relationship between the amount of mesh used to correct pelvic organ prolapse and stress urinary incontinence and subsequent complications and repeated interventions, researchers suggest. Dr. Art Sedrakyan of Weill Cornell Medical College in New York City told Reuters Health by email, "Currently, mesh used for pelvic organ prolapse is a class III (highest risk) device, upgraded from a class II (intermediate risk) device.